1. Home
  2. PHUN vs AVTX Comparison

PHUN vs AVTX Comparison

Compare PHUN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHUN
  • AVTX
  • Stock Information
  • Founded
  • PHUN 2009
  • AVTX 2011
  • Country
  • PHUN United States
  • AVTX United States
  • Employees
  • PHUN N/A
  • AVTX N/A
  • Industry
  • PHUN EDP Services
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHUN Technology
  • AVTX Health Care
  • Exchange
  • PHUN Nasdaq
  • AVTX Nasdaq
  • Market Cap
  • PHUN 88.8M
  • AVTX 88.4M
  • IPO Year
  • PHUN N/A
  • AVTX 2015
  • Fundamental
  • Price
  • PHUN $3.85
  • AVTX $7.09
  • Analyst Decision
  • PHUN Strong Buy
  • AVTX Strong Buy
  • Analyst Count
  • PHUN 3
  • AVTX 4
  • Target Price
  • PHUN $13.00
  • AVTX $33.00
  • AVG Volume (30 Days)
  • PHUN 734.1K
  • AVTX 43.8K
  • Earning Date
  • PHUN 03-11-2025
  • AVTX 03-28-2025
  • Dividend Yield
  • PHUN N/A
  • AVTX N/A
  • EPS Growth
  • PHUN N/A
  • AVTX N/A
  • EPS
  • PHUN N/A
  • AVTX N/A
  • Revenue
  • PHUN $3,537,000.00
  • AVTX $820,000.00
  • Revenue This Year
  • PHUN N/A
  • AVTX N/A
  • Revenue Next Year
  • PHUN $93.33
  • AVTX N/A
  • P/E Ratio
  • PHUN N/A
  • AVTX N/A
  • Revenue Growth
  • PHUN N/A
  • AVTX N/A
  • 52 Week Low
  • PHUN $2.85
  • AVTX $4.18
  • 52 Week High
  • PHUN $17.99
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • PHUN 40.80
  • AVTX 39.94
  • Support Level
  • PHUN $3.56
  • AVTX $7.42
  • Resistance Level
  • PHUN $4.03
  • AVTX $8.00
  • Average True Range (ATR)
  • PHUN 0.19
  • AVTX 0.60
  • MACD
  • PHUN 0.02
  • AVTX -0.02
  • Stochastic Oscillator
  • PHUN 50.00
  • AVTX 3.90

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: